Ambrx Biopharma's ARX788 Selected For Phase 2 Adaptive Breast Cancer Trial
Quantum Leap Healthcare Collaborative and Ambrx Biopharma Inc (NYSE:AMAM) have announced the selection of Ambrx's antibody-drug conjugate (ADC) ARX788 for a new investigational treatment arm in the I-SPY 2.2 TRIAL. Sponsored by Quantum Leap, I-SPY 2.2 is an adaptive Phase 2 trial that evaluates emerging targeted agents, allowing those agents to either be combined…
Benzinga ·
Benzinga
